Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...

In a study by the Northwestern Medicine Canning Thoracic Institute in Chicago, the RNA in the SARS-CoV-2 virus was found to "trigger the development of a unique type of immune cell with anti-cancer ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

The results show that long-term use of antihypertensive drugs, cholesterol-lowering drugs, diuretics and blood-thinning drugs ...

The results show that long-term use of antihypertensive drugs, cholesterol-lowering drugs, diuretics and blood-thinning drugs ...

The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...

Managing diabetes and high cholesterol often requires lifestyle changes, such as eating healthier, exercising, and sometimes ...

Salk scientists have tracked the flow of trans fats using mouse models to describe the molecular mechanisms that cause trans ...

Eating plant-based foods that are rich in fiber and healthy fats through what’s long been known as the portfolio diet is one ...